Macrocure (MCUR) Climbs to Session High
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Macrocure (NASDAQ: MCUR) gained Monday morning, rising 30%. Earlier Leap Therapeutics announced the presentation of top-line data from its clinical trial of DKN-01 combination therapy in patients with cholangiocarcinoma at ESMO.
Previously Leap has signed a merger agreement with Macrocure.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla (TSLA) Posts Q3 adj.-EPS of 71c
- VMware (VMW) October weekly volatility elevated into Q3 and outlook
- UPDATE: Dr Pepper Snapple Group (DPS) Said in Talks to Buy Bai Brands - Reuters
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!